202 related articles for article (PubMed ID: 24218548)
1. Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition.
Kirkpatrick DS; Bustos DJ; Dogan T; Chan J; Phu L; Young A; Friedman LS; Belvin M; Song Q; Bakalarski CE; Hoeflich KP
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19426-31. PubMed ID: 24218548
[TBL] [Abstract][Full Text] [Related]
2. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
[TBL] [Abstract][Full Text] [Related]
3. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
[TBL] [Abstract][Full Text] [Related]
4. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J
Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661
[TBL] [Abstract][Full Text] [Related]
5. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.
Zou ZQ; Zhang LN; Wang F; Bellenger J; Shen YZ; Zhang XH
Mol Med Rep; 2012 Feb; 5(2):503-8. PubMed ID: 22101421
[TBL] [Abstract][Full Text] [Related]
6. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
7. The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells.
Nováková J; Talacko P; Novák P; Vališ K
Cells; 2019 Feb; 8(2):. PubMed ID: 30795621
[TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity enrichment coupled to quantitative mass spectrometry reveals ubiquitin-mediated signaling events.
Yu K; Phu L; Varfolomeev E; Bustos D; Vucic D; Kirkpatrick DS
J Mol Biol; 2015 Jun; 427(11):2121-34. PubMed ID: 25861760
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
10. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
11. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
[TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
13. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
Kwei KA; Baker JB; Pelham RJ
PLoS One; 2012; 7(9):e46518. PubMed ID: 23029544
[TBL] [Abstract][Full Text] [Related]
14. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
Hofmann I; Weiss A; Elain G; Schwaederle M; Sterker D; Romanet V; Schmelzle T; Lai A; Brachmann SM; Bentires-Alj M; Roberts TM; Sellers WR; Hofmann F; Maira SM
PLoS One; 2012; 7(8):e44146. PubMed ID: 22952903
[TBL] [Abstract][Full Text] [Related]
15. Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.
Dogan T; Gnad F; Chan J; Phu L; Young A; Chen MJ; Doll S; Stokes MP; Belvin M; Friedman LS; Kirkpatrick DS; Hoeflich KP; Hatzivassiliou G
J Biol Chem; 2017 Sep; 292(35):14311-14324. PubMed ID: 28655764
[TBL] [Abstract][Full Text] [Related]
16. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract][Full Text] [Related]
17. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
18. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
20. The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Haagensen EJ; Thomas HD; Wilson I; Harnor SJ; Payne SL; Rennison T; Smith KM; Maxwell RJ; Newell DR
PLoS One; 2013; 8(12):e81763. PubMed ID: 24339963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
